Next year Medicare will be able to negotiate with drug companies on 25 of the most commonly used drugs. Now, again, this only affects Medicare recipients. But like you said, With the $35 a month cap on insulin drugs, that again was only supposed to apply to Medicare. But what we have witnessed is that insulin manufacturers have now extended that price cap across the board to non Medicare recipients. (10:50–10:57)
CLAIM
Asserts that the $35 monthly insulin cap was initially intended for Medicare recipients.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
